Lipodystrophy syndromes (CGL + AGL + FPLD + APL)

What changes during this transition

Lipodystrophy syndromes are a heterogeneous family of disorders defined by partial or near-total loss of adipose tissue and the cardiometabolic chaos that follows: severe insulin resistance, extreme hypertriglyceridemia (often >1000 mg/dL in generalized forms), recurrent pancreatitis, hepatic steatosis/NASH, difficult-to-control diabetes (often requiring 1000+ units/day of insulin in CGL/AGL), premature atherosclerotic cardiovascular disease, and in some subtypes hypertrophic cardiomyopathy + arrhythmias that drive mortality. The syndromes cluster into four families. CONGENITAL GENERALIZED LIPODYSTROPHY (CGL, Berardinelli-Seip syndrome) is autosomal recessive with near-total adipose absence from birth: CGL1 (AGPAT2, adipogenesis defect), CGL2 (BSCL2/seipin, adipocyte differentiation, sometimes with intellectual disability), CGL3 (CAV1/caveolin-1), CGL4 (PTRF/CAVIN1, often with muscular dystrophy + hypertrophic cardiomyopathy + arrhythmias). ACQUIRED GENERALIZED LIPODYSTROPHY (AGL, Lawrence syndrome) is the autoimmune-spectrum acquired form with similar metabolic severity. FAMILIAL PARTIAL LIPODYSTROPHY (FPLD) is autosomal dominant with partial fat loss (typically extremities) and truncal/central accumulation — FPLD2 (Dunnigan-Köhler from LMNA mutations) is the most common subtype, often presenting in females at puberty with progressive fat redistribution; FPLD1 (Köbberling), FPLD3 (PPARG), FPLD4 (PLIN1), FPLD5 (CIDEC), FPLD6 (LIPE), and additional subtypes round out the genetic landscape; LMNA mutations also cause progeria/cardiomyopathy syndromes. ACQUIRED PARTIAL LIPODYSTROPHY (APL, Barraquer-Simons syndrome) presents with cephalothoracic lipoatrophy + lower-body fat preservation + complement C3 nephritic factor + membranoproliferative glomerulonephritis. HIV-ASSOCIATED LIPODYSTROPHY emerged from older antiretroviral regimens with central fat accumulation + peripheral lipoatrophy + metabolic syndrome — and is specifically the indication for tesamorelin's FDA approval. Diagnostic workup is anchored by clinical phenotype + DEXA or MRI fat quantification + targeted genetic testing + autoantibody + complement studies + comprehensive metabolic panel (fasting glucose, HbA1c, insulin, C-peptide, triglycerides, lipid profile, LFTs, leptin, adiponectin) + cardiovascular workup (echo + EKG + ambulatory monitor). Management is multidisciplinary: aggressive dietary fat restriction (CRITICAL for triglyceride control + pancreatitis prevention in CGL/AGL), insulin sensitizers (metformin + thiazolidinediones with pioglitazone caution in heart failure), often extreme insulin doses, GLP-1 agonists off-label for FPLD metabolic management, fibrates (fenofibrate) for hypertriglyceridemia, statins, ACE/ARB for albuminuria, and cardiomyopathy management. Two peptide therapies are FDA-approved standards-of-care in this disease family and Juno names them explicitly. METRELEPTIN (Myalept, Aegerion/Amryt) is a recombinant leptin analog FDA-approved February 2014 for GENERALIZED LIPODYSTROPHY (CGL + AGL) — the first FDA-approved leptin therapy, replacing the deficient leptin signaling that drives hyperphagia + insulin resistance in this population; daily subcutaneous injection; access is REMS-controlled for lymphoma risk + severe infection risk + neutralizing antibody risk; access runs through specialty pharmacy. Metreleptin is not approved for partial lipodystrophy (FPLD/APL). Responders see dramatic improvements in HbA1c, triglycerides, hepatic steatosis, and ovarian function. TESAMORELIN (Egrifta, Theratechnologies) is a GHRH analog FDA-approved in 2010 specifically for HIV-ASSOCIATED LIPODYSTROPHY (truncal/visceral adiposity reduction, ~15% VAT reduction over 26 weeks). The HIV-LD approval does NOT propagate to non-HIV lipodystrophy syndromes — off-label use in CGL/AGL/FPLD/APL occurs but the evidence base is thin, and the label contraindicates active malignancy and pituitary tumor history. Community + anti-aging clinic peptide framing reaches toward two directions that need substrate addressing. First, off-label tesamorelin use beyond HIV-LD: the FDA approval is indication-specific and Rule 6 (regulatory approval doesn't propagate across indications) applies — non-HIV lipodystrophy patients should engage with a lipodystrophy specialist about whether metreleptin (for generalized forms) is the indicated peptide, not extend the tesamorelin label by analogy. Second, the CJC-1295 + ipamorelin 'lipolysis' framing that's heavily marketed in community channels is mechanistically wrong-direction for lipodystrophy patients — when adipose tissue deficiency IS the disease, a protocol marketed for mobilizing lipid out of remaining adipose depots is conceptually opposed to what the patient needs, and GH-axis stimulation additionally worsens insulin resistance in a population that often already runs extreme insulin doses. Semaglutide and other GLP-1 agonists have growing off-label use for FPLD metabolic syndrome management with case-series + registry support — coordinate with the lipodystrophy specialist rather than self-direct, and watch for pancreatitis history as a load-bearing contraindication. Patient advocacy includes the International Society for Lipodystrophy, Lipodystrophy United, The Lipodystrophy Foundation, and broader rare-disease networks (AMEND); Endocrine Society 2016 guidelines (with 2024 update) anchor specialist practice. Editorial note: CGL is typically diagnosed in infancy, the visible adipose absence is psychologically distressing for families, FPLD2 (Dunnigan-Köhler) in females often presents at puberty with progressive fat redistribution that carries body-image weight alongside metabolic burden, recurrent pancreatitis + cardiomyopathy are mortality-relevant, and this is a heavy lifelong syndrome family — substrate framing across all peptides honors that weight. Sixty-sixth deliberate non-elevation of community peptides.